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Objectives The purpose of this study was to examine whether adding homocysteine (Hcy) to a model based on traditional
cardiovascular disease (CVD) risk factors improves risk classification.
Background Data on using Hcy to reclassify individuals in various risk categories beyond traditional approaches have not
been adequately scrutinized.
Methods We performed a post hoc analysis of the MESA (Multi-Ethnic Study of Atherosclerosis) and NHANES III (National
Health and Nutrition Examination Survey III) datasets. Hcy was used to predict composite CVD and hard coronary
heart disease (CHD) events in the MESA study and CVD and CHD mortality in the NHANES III survey using ad-
justed Cox-proportional hazard analysis. Reclassification of CHD events was performed using a net reclassifica-
tion improvement (NRI) index with a Framingham risk score (FRS) model with and without Hcy.
Results Hcy level (15 mol/l) significantly predicted CVD (adjusted hazard ratio [aHR]: 1.79, 95% confidence intervals
[CI]: 1.19 to 1.95; p  0.006) and CHD events (aHR: 2.22, 95% CI: 1.20 to 4.09; p  0.01) in the MESA trial
and CVD (aHR: 2.72, 95% CI: 2.01 to 3.68; p  0.001) and CHD mortality (aHR: 2.61, 95% CI: 1.83 to 3.73; p 
0.001) in the NHANES III, after adjustments for traditional risk factors and C-reactive protein. The level of Hcy,
when added to FRS, significantly reclassified 12.9% and 18.3% of the overall and 21.2% and 19.2% of the
intermediate-risk population from the MESA and NHANES cohorts, respectively. The categoryless NRI also
showed significant reclassification in both MESA (NRI: 0.35, 95% CI: 0.17 to 0.53; p  0.001) and NHANES III
(NRI: 0.57, 95% CI: 0.43 to 0.71; p  0.001) datasets.
Conclusions From these 2 disparate population cohorts, we found that addition of Hcy level to FRS significantly improved risk
prediction, especially in individuals at intermediate risk for CHD events. (J Am Coll Cardiol 2011;58:1025–33)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.028Cardiovascular disease (CVD) is the leading cause of
mortality in the United States, accounting for more than
one-third of all deaths (1). Although traditional risk
factors account for most of the CVD risk, prediction
models such as the Framingham risk score (FRS) are
inherently limited in their ability to discriminate among
individuals who will or will not experience adverse CVD
events (2,3). Evidently, significant residual risk for CVD
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accepted May 20, 2011.exists in the population independent of these risk fac-
tors (4,5).
See page 1034
To better comprehend and eliminate this residual risk,
hosts of novel risk factors and biomarkers have been studied
to date. Some of these emerging markers, such as C-reactive
protein (CRP), an inflammatory biomarker (6,7); concen-
tration of coronary artery calcium (CAC) (8); and level of
homocysteine (Hcy), an amino acid that can be easily and
reliably measured in human plasma (5,9), have shown
promise (5,10,11). Indeed, several follow-up and case-
control studies, as well as meta-analyses, have attempted to
profile the risk conferred by Hcy level with inconsistent
results. Of note, the large majority of these studies stemmed
from predominantly Caucasian cohorts or individuals with
preexisting cardiac disease (11–14).
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Homocysteine and CHD Risk Classification August 30, 2011:1025–33To date, no study has systemat-
ically explored the predictive value
of Hcy beyond existing risk pre-
dicted by the FRS (particularly in
individuals without overt CVD) or
assessed whether Hcy level con-
tributes to reclassification of in-
dividuals in the intermediate-risk
FRS category. These deficiencies
were highlighted in the recent
U.S. Preventive Services Task
Force (USPSTF) recommenda-
tion statement for nontraditional
risk factors in coronary heart dis-
ease (CHD) risk assessment (5).
Accordingly, we sought to de-
fine: 1) the predictive value of
Hcy levels in predicting CV out-
comes in a community-based,
multiethnic, healthy U.S. adult
population and a population co-
hort representative of U.S. adults;
and 2) the incremental value, if any, of adding Hcy level to the
FRS for CHD risk prediction.
Methods
Study cohorts. THE MESA STUDY. MESA (Multiethnic
tudy of Atherosclerosis) was a population-based study
n  6,814) of individuals belonging to various ethnicities,
anging between 45 and 84 years of age at study enrollment,
ithout a prior history of clinical CVD. After obtaining
nstitutional review board approval, we undertook a post hoc
nalysis of the MESA Limited Access dataset, obtained
rom the National Heart, Lung, and Blood Institute. A
etailed description of the study design, methods, and
bjectives has been published previously (15). In brief, the
ESA study was designed to identify the characteristics of
ubclinical CVD and risk factors that predict progression to
linically overt CVD or progression of the subclinical
isease. After excluding patients with missing data, we
dentified 6,450 adults.
Plasma Hcy levels were measured using a fluorescence
olarization immunoassay (IMx Hcy assay, Axis Biochem-
cals ASA, Oslo, Norway) with the IMx analyzer (Abbott
iagnostics, Abbott Park, Illinois). High-sensitivity
-reactive protein (hs-CRP) was measured using a BNII
ephelometer (Dade Behring, Deerfield, Illinois). Assays
ere performed exclusively at the Biochemical Genetics
linical Laboratory, Fairview-University Medical Center
Minneapolis, Minnesota). Details of blood sample collec-
ion and analyses are provided elsewhere (16).
Demographic information was obtained using standard
uestionnaires. The endpoints were defined per the MESA
teering committee protocol. All CVD events and hard
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CHD  coronary heart
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
FRS  Framingham risk
score
Hcy  homocysteine
hs-CRP  high-sensitivity
C-reactive protein
IDI  integrated
discrimination index
NRI  net reclassification
index
USPSTF  U.S. Preventive
Services Task ForceHD events were considered the primary outcomes ineparate survival analyses. All CVD events was a composite
utcome consisting of myocardial infarction, resuscitated
ardiac arrest, definite angina, probable angina (if followed
y revascularization), stroke, stroke death, CHD death,
ther atherosclerotic death, and other CVD death. A hard
HD event was defined as myocardial infarction, resusci-
ated cardiac arrest, or CHD death.
THE NHANES III STUDY. NHANES III (National Health
nd Nutrition Examination Survey III) was a longitudinal
tudy of noninstitutionalized nationally representative indi-
iduals surveyed between 1988 and 1994. The protocols for
he NHANES III study were approved by the National
enter for Health Statistics ethics/institutional review
oard, and all participants who underwent standardized
nterviews, physical examinations, and various laboratory
easurements signed an informed consent (17).
Hcy levels were measured using the high-performance
iquid chromatography method as described by Araki and
ako (18). CRP was measured using latex-enhanced
ephelometry in the NHANES III population (not
s-CRP). Detailed descriptions of the data collection and
aboratory methods have been described elsewhere (19).
t is worth noting that different biochemical assays were
sed to measure serum Hcy levels in the MESA and
HANES populations; however, earlier research has
hown that no significant differences exist in their ana-
ytic performance (20).
Mortality data were ascertained using the National Death
ndex and are available through the National Center for
ealth Statistics record linkage program. The primary
utcome of interest was mortality due to CVD and CHD.
VD mortality was defined as death due to ischemic heart
isease, cerebrovascular disease, and atherosclerotic heart
isease, whereas CHD mortality included death due to
schemic heart disease only (21).
tatistical analysis. Distribution of baseline characteristics
cross Hcy categories (category 1:10 mol/l; 2: 10 to 14.9
mol/l; and 3: 15 mol/l) was compared using the
hi-square test for categorical variables (%) and 1-way
nalysis of variance for continuous variables (mean  SD).
All covariates were tested for normality by visual inspection
using frequency distribution curves. Log transformations
were performed to normalize Hcy and CRP levels. To assess
the predictive role of Hcy, adjusted multivariable Cox
proportional hazard models were generated as follows:
model 1: Hcy  age, sex, and race; model 2: model 1 
body mass index (BMI), systolic blood pressure, current
smoking, high-density lipoprotein cholesterol, total choles-
terol, lipid-lowering therapy, diabetes, and use of antihy-
pertensive therapy; model 3 included variables in model 2
and log(CRP); and model 4 included variables in model 2
and creatinine. Assumption of proportionality for all of the
models was tested using Schoenfeld residuals, which was
found to be statistically nonsignificant. Furthermore, we
also performed formal statistical analyses for the interaction
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August 30, 2011:1025–33 Homocysteine and CHD Risk Classificationbetween sex and Hcy and ethnicity and Hcy to evaluate for
any effect modification. We found the interaction to be
statistically nonsignificant, suggesting no sex or ethnic
variation in the predictive value of Hcy on CV outcomes.
Hazard ratios were also estimated for CRP using similar
analyses.
We then assessed whether the addition of Hcy level to
FRS (calculated for each individual using adult treatment
panel III guidelines [22]) resulted in better predictive
accuracy for CHD events. To assess discrimination, which
provides information about whether the new marker has an
ability to differentiate among individuals who do and do not
experience an event, we generated area under the receiver
operating characteristics (AU-ROC) curves for models with
and without Hcy. We also calculated the Harrell c-statistic,
which allows censored data and permits appraisal of the
predictive accuracy for the model with and without Hcy.
Similar analysis was performed for CRP. Considering the
drawbacks of ROC curves, which need a large odds ratio for
even a small improvement, we further assessed measures
that may have clinical impact by reclassification, such as the
net reclassification index (NRI) and integrated discrimina-
tion index (IDI) (23,24).
NRI calculation. MESA POPULATION. The estimated risk
or 6 years of follow-up in the MESA cohort was calculated
sing multivariate logistic analysis. Because the FRS pro-
ides estimates for 10-year risk, we divided the risk esti-
ates by 1.67 to obtain 6-year estimated risk in the MESA
ohort. This approximation might result in a slightly higher
ncidence rate for a given age and risk factor level at entry,
ut it allowed us to compare the primary outcome variable
uring a defined period of observation instead of extending
t beyond the actual follow-up duration (25). Recalibrated
isk categories for 6-year estimated Framingham risk were
s follows: very low: 3%, low: 3% to 6%, intermediate:
Baseline Characteristics Distribution Across Homocysteine CategoTable 1 Baseline Characteristics Distribution Across Homocyst
MESA Cohort (N  6,450
Serum homocysteine, mol/l <10 10–14.9 >15
Age, yrs 60.5 9.8 65.4 10.1 68.1
Male 40.9 60.5 60.3
Hypertension 39.6 54.1 62.3
Diabetes mellitus 10.9 14.6 19.5
Hyperlipidemia 37.8 36.6 36.3
History of smoking 47.5 52.9 56.9
Use of lipid-lowering therapy 15.0 17.6 23.9
Antihypertensive medication use 31.9 46.8 55.2
Body mass index, kg/m2 28.2 5.5 28.4 5.2 28.3
Systolic blood pressure, mm Hg 125 21 130 22 132
Total cholesterol, mg/dl 195 34 192 36 189
HDL-C, mg/dl 52 15 50 14 49
CRP, mg/l* 3.7 5.4 3.4 4.8 3.4
Serum creatinine, mg/dl† 0.89 0.20 1.05 0.20 1.32
Data are mean  SD or %. *C-reactive protein (CRP) data are available for 5,783 participants only
re available for 5,772 participants only in the NHANES III cohort. CRP (not high-sensitivity CRP) w
he MESA (Multi-Ethnic Study of Atherosclerosis) population (high-sensitivity CRP).
HDL-C  high-density lipoprotein cholesterol.% to 12%, and high: 12%, based on the third report of
he National Cholesterol Education Program Expert Panel
n Detection, Evaluation, and Treatment of High Blood
holesterol in Adults Framingham point scoring (22).
NHANES POPULATION. The estimated risk for 10 years of
ollow-up, adjusted from 15 years of follow-up, in the
HANES cohort was also calculated using multivariate
ogistic analysis. The following risk categories were ana-
yzed: very low: 5%, low: 5% to 10%, intermediate: 10%
o 20%, and high: 20%, as described earlier (22). The
RI for CHD events, as described by Pencina et al. (23),
as calculated by comparing estimated risk probabilities
erived from multivariate logistic models incorporating FRS
ith and without Hcy level.
Individuals were then compared based on their classifi-
ations by these 2 models. The NRI was calculated for the
ntire cohort and the intermediate-risk category. Statistical
ignificance for all components of NRI and overall NRI was
ested by calculating the Z score for discordance in a manner
nalogous to the McNemar test. Two-tailed p values 0.05
ere considered statistically significant. We also calculated
he IDI, which provides information about the probability
ifferences in the discrimination slopes of events and non-
vents by a new marker (23). It can be expressed as (EY1 
X1)  (EX0  EY0), in which EY1 and EY0 represent
he mean expected probabilities of events and nonevents,
espectively, for the model including the new marker, and
X1 and EX0 are the mean expected probabilities of events
nd nonevents, respectively, for the model without the new
arker. Relative IDI, an index calculated when the inci-
ence of events is relatively small, is defined as ([EY1 
Y0]/[EX1  EX0])  1. We further analyzed both of the
ohorts for improvement in “categoryless” NRI, which is a
ecently proposed analytic measure applicable to time to
n the MESA and NHANES III CohortsCategories in the MESA and NHANES III Cohorts
NHANES III Cohort (N  6,797)
p Value <10 10–14.9 >15 p Value
0.001 42.3 16.8 51.9 19.5 57.8 21.0 0.001
0.001 35.86 54.87 57.7 0.001
0.001 22.3 37.3 47.8 0.001
0.001 9.7 11.4 13.3 0.008
0.606 26.1 32.7 32.2 0.001
0.001 41.9 53.2 57.7 0.001
0.001 1.9 3.8 4.3 0.001
0.001 10.3 18.5 26.8 0.001
0.519 27.5 6.2 27.6 5.8 26.7 5.7 0.005
0.001 120 19 128 22 133 25 0.001
0.001 200 44 208 44 205 44 0.001
0.001 51 15 50 16 52 19 0.011
0.270 4.9 7.6 4.6 7.3 6.9 16.4 0.001
0.001 1.17 0.20 1.31 0.40 1.52 0.80 0.001
NHANES III (National Health and Nutrition Examination Survey III) cohort. †Serum creatinine data
sured using latex-enhanced nephelometry in the NHANES III population and BNII nephelometry inries ieine
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Homocysteine and CHD Risk Classification August 30, 2011:1025–33event data (24). As the name suggests, categoryless NRI
does not depend on pre-defined risk categories and mea-
sures upward and downward reclassification as any change
in predicted probabilities derived from the model without
and with the new marker. Reclassification 0 for events
(1) and 0 for nonevents (1) is classified as improve-
ment, with the maximum possible value of 1  1  2 and
the opposite as nonimprovement.
To assess calibration, which provides information about
how closely the predicted probabilities of estimated risk by
the novel biomarker reflect the actual observed risk, we
performed a Hosmer-Lemeshow chi-square test for models
with and without Hcy. A predictive model with calibration
estimates of less than 20 is considered to be a model with
adequate calibration. We also performed a 2 log likeli-
hood ratio test and the Bayesian information criterion,
which provides information about the probability that a
given independent variable is a part of the true model, to
assess the global fit of the models. All statistical analysis was
performed using STATA version 10 (StataCorp, College
Station, Texas).
Results
Baseline characteristics for the MESA cohort. Table 1
summarizes the baseline characteristics of the 2 study
cohorts. In the MESA cohort, there was a graded increase
in mean age and systolic blood pressure and a decrease in
total cholesterol and high-density lipoprotein cholesterol
with increasing Hcy categories. Proportions of patients with
hypertension or diabetes, smokers, and those using lipid-
lowering therapy increased with increasing Hcy categories.
In the NHANES cohort, similar results were found for age,
systolic blood pressure, and patients with hypertension or
diabetes, smokers, and those using lipid-lowering therapy.
We found that mean total cholesterol and the proportion of
men increased with increasing Hcy categories in the
NHANES cohort.
Hcy and CV risk. MESA COHORT. Table 2 shows Hcy
oncentration as a predictor of CV events in the MESA
ohort. As shown, when Hcy was evaluated as a continuous
ariable, each 0.1 log-unit increase in Hcy level was associ-
ted with an adjusted hazard ratio (aHR) of 1.87 (95%
onfidence interval [CI]: 1.29 to 2.69; p  0.001) for all
VD events and 2.90 (95% CI: 1.69 to 4.95; p 0.001) for
ard CHD events. Higher Hcy level was also significantly
ssociated with a higher incidence of all CVD (aHR: 1.79,
5% CI: 1.19 to 1.95; p  0.006 in category III vs. I) and
hard CHD events (category III vs. I: model 3 aHR: 2.22,
95% CI: 1.20 to 4.09; p  0.011) after adjustments when
evaluated as a categorical variable.
NHANES COHORT. Table 3 shows Hcy as a predictor of
VD deaths in the NHANES cohort. As shown, when
cy was evaluated as a continuous variable, each 0.1
og-unit increase in Hcy was associated with an aHR of 1.97
95% CI: 1.52 to 2.55; p 0.001) for CVD deaths and 1.95 Ho T A H *A
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August 30, 2011:1025–33 Homocysteine and CHD Risk Classification[95% CI: 1.43 to 2.64; p 0.001) for CHD deaths. Higher
Hcy level was significantly associated with a higher inci-
dence of CVD mortality (aHR: 2.72; 95% CI: 2.01 to 3.68;
p  0.001 in category III vs. I) and CHD mortality
(category III vs. I: model 3 aHR: 2.61, 95% CI: 1.83 to
3.73; p  0.001) when evaluated as a categorical variable.
Further, no attenuation of HRs was observed following
adjustments for serum creatinine in either cohort. Upon
similar analyses, CRP was not found to be a significant
predictor of CVD/CHD events (data not shown).
Table 4 details the calibration properties of the model
with a new marker (Hcy); as shown, the addition of Hcy
level to FRS significantly improved Bayesian information
criterion, along with a statistically significant likelihood
ratio test.
Risk stratification and restratification. In the ROC anal-
ysis for the MESA cohort, the c-statistic for the model with
FRS alone was 0.745, which increased significantly with the
addition of Hcy level (c-statistic of 0.760; p for improve-
ment 0.001). A similar magnitude of effect was observed
in the NHANES cohort (c-statistic increased from 0.844 to
0.868 after Hcy level was added to FRS; p  0.001). The
AU-ROC curve also improved significantly after addition of
Hcy level to FRS compared with the FRS alone for both
MESA and NHANES cohorts (Table 4). There was no
significant increment in either AU-ROC or c-statistic when
CRP level was added to FRS in either cohort, and hence,
newer reclassification indexes were not attempted (data not
shown).
Upon examining the reclassification properties of Hcy,
we observed an overall improvement in the net risk strati-
fication of up to 12.9% (number of participants reclassified
of overall sample was 832) in the MESA cohort and 18.3%
(number of participants reclassified of overall sample was
1,243) in the NHANES cohort (p  0.001 for both). For
individuals at intermediate risk of events, the net reclassifi-
cation was 21.2% in the MESA cohort and 19.1% in the
NHANES cohort (p  0.001 for both) (Tables 5 and 6).
Overall, the absolute IDI for the MESA cohort was 0.006
(p for improvement 0.001) and 0.015 (p for improvement
0.001) for the NHANES cohort, with relative IDIs of
46% and 33% in the MESA and NHANES cohorts,
respectively.
The categoryless NRI also improved significantly for both
the MESA (0.35, 95% CI: 0.17 to 0.53; p  0.001) and
NHANES (0.57, 95% CI: 0.43 to 0.71; p 0.001) cohorts;
the improvement was largely driven by downward reclassi-
fication of nonevents (83% in the MESA and 67% in the
NHANES cohorts).
Discussion
To our knowledge, these observations represent the only
analyses of Hcy and CV risk in 2 large, low-risk, multieth-
nic, representative U.S. populations to date. Our results lend
support to previously published data exploring the associa-Ho T A
H
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NRI 
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Homocysteine and CHD Risk Classification August 30, 2011:1025–33tion between Hcy and CVD and CHD events. Of note,
unlike any previous study, our analyses were adjusted for
CRP, an independent predictor of future CVD events
(11,13,26,27).
Hcy and CV risk assessment. The FRS has been charac-
terized in relation to Hcy level with variable results. In a
study by Kullo et al. (28), Hcy was significantly associated
with CAC in individuals with intermediate risk (6% to 20%)
and was shown to be highly predictive of CV mortality in
the very elderly, independent of conventional risk factors
(29). On the other hand, a more recent study by Wilson et
al. (6) showed that use of Hcy level in CVD risk assessment
Comparison of Risk Prediction Models With FRSWithout Homocysteine in the MESA and NHANETable 4 Comparison of Risk Prediction ModWithout Homocysteine in the MESA
Hard CHD Event
FRS FRS
Discrimination
C-statistic 0.745
Area under the curve 0.742
Absolute IDI 0.006 (p 
Relative IDI 46%
Categoryless NRI
Index statistic (95% CI) 0.35 (0.17–0.53;
Calibration
Likelihood ratio test, p value 0.001
Bayes information criterion 55,398.277
FRS  Framingham risk score; IDI  integrated discrimination index;
6-Year Risk of Hard CHD Event in the MESA Population in ModelsTable 5 6-Year Risk of Hard CHD Event in the MESA Populatio
Model
Model Without Homocysteine 0% to <3% 3% to <6%
0% to 3%
Persons included 5,476 264
No. of events 69 16
No. of nonevents 5,407 248
3% to 6%
Persons included 150 296
No. of events 3 18
No. of nonevents 147 280
6% to 12%
Persons included 1 36
No. of events 0 2
No. of nonevents 1 34
12%
Persons included 0 0
No. of events 0 0
No. of nonevents 0 0
Total
Persons included 5,627 598
No. of events 72 36
No. of nonevents 5,555 562
Net reclassification improvement
Overall
Intermediate riskNA  not applicable; other abbreviations as in Tables 1 and 2.did not improve predictive accuracy for discrimination of
events in the Framingham Offspring Study population. In
contrast, Hcy level significantly improved risk prediction
beyond the FRS in our study involving 2 disparate, large,
multiethnic U.S. populations.
Data on the impact of Hcy level when added to the FRS
to reclassify individuals at intermediate risk are essentially
lacking (5,30). Numerous recent reports employing novel
risk metrics such as brachial flow-mediated dilation, CAC,
and CRP have attempted to reclassify CVD risk beyond the
FRS, with mixed results. Compared with the FRS alone,
the addition of flow-mediated dilation (25) and CAC (31)
h andCohortsith FRS With and
NHANES III Cohorts
ESA Hard CHD Deaths in NHANES III
mocysteine FRS FRS  Homocysteine
0.760 0.844 0.868
0.758 0.832 0.857
) 0.015 (p  0.001)
33%
001)* 0.57 (0.43–0.71; p  0.001)*
0.001*
13.542 58,419.864 58,460.642
net reclassification index; other abbreviations as in Tables 1 and 2.
and Without Homocysteineodels With and Without Homocysteine
Homocysteine Risk Reclassification
6% to <12% >12% Total Higher Lower
20 5 5,765
2 0 87 18 NA
18 5 5,678 271 NA
62 6 516
3 1 25 4 3
59 5 491 64 147
80 8 125
6 2 10 2 2
74 6 115 6 35
7 37 44
0 2 2 NA 0
7 35 42 NA 7
169 56 6,450
11 5 124 24 5
158 51 6,326 341 189
12.9% (p  0.001)
21.2% (p  0.001)WitS IIIels W
and
s in M
 Ho
0.001
p  0.
*
55,4Withn in M
With
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August 30, 2011:1025–33 Homocysteine and CHD Risk Classificationto the FRS has resulted in NRI values of 29% and 28% and
25% and 55% in overall study samples and subjects at
intermediate risk, respectively. In this context, our results
are comparable in magnitude and are encouraging, with an
overall NRI of 12.9% and 18.3% and for intermediate-risk
category NRI values of 21.2% and 19.1% for MESA and
NHANES cohorts, respectively. Furthermore, upon analyz-
ing Hcy level for improvement in the categoryless NRI, a
measure that is applicable to time to events data and is
independent of pre-defined risk categories, we observed
significant reclassification in both cohorts (Table 4). This is
particularly important when the relative ease of obtaining an
Hcy level is juxtaposed against radiation exposure and the
expense involved in obtaining an individual’s CAC score
(31). Of note, our analysis in the MESA and NHANES
cohorts showed that hs-CRP and CRP, respectively, were
not independent predictors of CHD events, with no signif-
icant increment in AU-ROC or c-statistic. These findings
are in sharp contrast to that of a previous study using
hs-CRP, which reported an NRI of 5.6% for CVD and
11.8% for hard CHD events (6).
Homocysteine: biomarker or risk factor? Current guide-
lines do not support the use of Hcy level for CVD risk
stratification. Indeed, a debate as to whether Hcy should be
viewed as a risk factor or a biomarker still exists. Observa-
tional studies have revealed an association between plasma
Hcy and CVD events, whereas several randomized con-
Ten-Year Risk of CHD Death in the NHANES III Population in ModeTable 6 Ten-Year Risk of CHD Death in the NHANES III Populat
Model
Model without Homocysteine 0% to <5% 5% to <10%
0% to 5%
Persons included 5,273 229
No. of events 53 31
No. of nonevents 5,220 188
5% to 10%
Persons included 264 460
No. of events 9 41
No. of nonevents 237 419
10% to 20%
Persons included 7 108
No. of events 0 14
No. of nonevents 7 419
20%
Persons included 0 1
No. of events 0 0
No. of nonevents 0 1
Total
Persons included 5,526 788
No. of events 62 86
No. of nonevents 5,464 702
Net reclassification improvement
Overall
Intermediate
Abbreviations as in Tables 1, 2, and 5.trolled trials and a recent meta-analysis have shown thatHcy-lowering interventions did not reduce the occurrence
of CVD events, especially CHD (32–37). However, it
should be noted that although the duration of observational
studies exceeded a decade, most of the interventional trials
have had a limited follow-up of 5 years. Such truncated
follow-up periods may not permit definitive comments on
risk reduction, particularly when one considers the natural
history of atherosclerosis, a process that could take decades
to progress from plaque formation to a clinical event (32).
Further, the majority of these interventional trials re-
cruited patients with pre-existing CVD or a risk equiv-
alent (34). This bias is reflected in the recent USPSTF
statement on screening for intermediate risk factors for
CHD: “all trials to date have been of tertiary prevention
and conducted among individuals with prevalent CHD,
cerebrovascular disease or diabetes. Whether treatment of
elevated Hcy levels before an individual develops vascular
disease will be beneficial is not resolved by these trials of
tertiary prevention” (30). The USPSTF guidelines also
noted that “no studies calculated a Framingham risk
score, assessed predictive value beyond Framingham risk
scoring, or assessed whether homocysteine levels contrib-
ute to reclassification from intermediate to another risk
category” (5). The inference from the current guidelines
is that significant uncertainties in the applicability of Hcy
concentration for risk prediction of individuals at inter-
th and Without Homocysteinen Models With and Without Homocysteine
Homocysteine Risk Reclassification
10% to <20% >20% Total Higher Lower
32 5 5,529
4 1 89 36 NA
28 4 5,440 220 NA
114 6 826
18 1 69 19 9
96 5 757 101 237
217 64 396
22 7 43 7 14
96 57 353 57 426
19 26 46
1 2 3 NA 1
18 24 43 NA 19
382 101 6,797
45 11 204 62 24
337 90 6,593 378 357
18.3% (p  0.001)
19.1% (p  0.001)ls Wiion i
Withmediate risk exist; in this context, our results provide
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Homocysteine and CHD Risk Classification August 30, 2011:1025–33compelling and substantive evidence filling this void in
knowledge.
The USPSTF also pointed out that current guidelines
fail to account for differences in risk prediction among
racial and ethnic groups (5). For example, African Amer-
icans and Hispanics may need more aggressive interven-
tions for a particular risk score because of their high
absolute risk of CVD events relative to whites, who
accounted for most of the original Framingham cohort
(38). In contradistinction, FRS has been shown to
overestimate the risk of CHD among Chinese popula-
tions (39). Based on the available evidence, it appeared
imperative to investigate the effect modification by eth-
nicity on the association between Hcy and CV outcomes.
We found that the interaction term between ethnicity
and Hcy level was statistically nonsignificant for all CV
outcomes in both the NHANES and MESA cohorts, a
noteworthy finding suggesting that ethnicity might not
play a significant role when an individual’s risk for future
CV events is evaluated based on serum Hcy levels.
In these analyses, we prospectively validated and showed
the incremental value of Hcy level in predicting adverse
CVD events beyond the FRS, thereby fulfilling the criteria
set for a “novel” marker (40). Although specific interven-
tions aimed at lowering Hcy levels in individuals with
pre-existing CVD do not appear to be beneficial, similar
interventions pursued as part of a primary prevention
strategy are yet to be evaluated at this time. Because
aggressive risk reduction in individuals classified as high risk
has been shown to be beneficial (5), approaching individuals
as high risk, based on the reclassification using Hcy, may
also seem reasonable. Along these lines, it would seem
imprudent to discount the utility of Hcy in CVD risk
prediction solely because interventions to lower plasma Hcy
levels do not appear to favorably modulate the risk of
incident CVD. Although prospective research in this arena
is clearly warranted, elevated Hcy level should be construed
in the interim more as a biomarker portending elevated
CVD risk rather than a causally related “modifiable risk
factor” (32).
Study limitations. A single sample of Hcy was measured at
baseline in both the MESA and NHANES III cohorts.
Hcy levels are subject to variation based on food intake,
diurnal changes, and position during blood draw; these
variations might have led to nondifferential misclassification
and attenuation in effect sizes (9). Low cobalamin or folate
levels, which were not accounted for, could lead to elevated
Hcy (9). The possibility of unmeasured confounders and
residual confounding affecting study results cannot be ruled
out—such issues are inherent limitations of observational
cohort studies.
Conclusions
Our observations are novel and demonstrated that elevated
Hcy concentration predicts future CVD and CHD events indisparate, representative populations of U.S. adults across
ethnic subgroups. Our findings revealed that plasma Hcy
levels enhance risk prediction when added to the FRS,
enabling the reclassification of a significant number of
individuals at “intermediate risk” of CHD events.
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